Echo IQ (ASX:EIQ), an AI and medical tech firm from Sydney, has secured a US reimbursement code for its EchoSolv-AS technology. This move is a pivotal step in its US market strategy, enabling reimbursement between US$100 and US$150 per use.
Echo IQ's identification of a US reimbursement code marks a crucial advance in its plan to commercialize EchoSolv-AS. The reimbursement rate is higher than anticipated, offering significant revenue potential. The company is integrating its technology at a Harvard Medical School facility and preparing to secure a Category III CPT code by mid-2025. These efforts aim to broaden market access and enhance diagnostic capabilities for Aortic Stenosis in the U.S.
The securing of Miscellaneous Code 93799 is the first step towards broader reimbursement and commercial adoption in the U.S.